Introduction
Methods
Study design and participants
Patient evaluation
Conservative treatment and evaluation of response to progestin treatment
Construction and validation of the predictive model
Statistical analysis
Results
Characteristics of enrolled patients
Variables | Control group | CR group | P-value* |
---|---|---|---|
N = 20 | N = 173 | ||
Time to CR | 10.15 ± 7.55 | 6.28 ± 6.01 | 0.011 |
Age (year) | 33.60 ± 4.94 | 32.59 ± 5.02 | 0.222 |
BMI (kg/m2) | 30.03 ± 4.33 | 26.87 ± 4.97 | 0.003 |
SBP (mmHg) | 130.45 ± 17.31 | 123.05 ± 14.18 | 0.095 |
DBP (mmHg) | 84.50 ± 13.56 | 79.27 ± 9.44 | 0.064 |
PP (mmHg) | 45.95 ± 10.23 | 43.78 ± 9.95 | 0.322 |
FBG (mmol/L) | 5.60 ± 3.04 | 5.41 ± 3.08 | 0.700 |
Serum insulin (mmol/L) | 29.79 ± 21.58 | 17.00 ± 11.31 | 0.001 |
TG (mmol/L) | 1.52 ± 0.84 | 1.57 ± 0.95 | 0.815 |
HDL (mmol/L) | 1.12 ± 0.23 | 1.17 ± 0.33 | 0.599 |
Cholesterol (mmol/L) | 5.18 ± 0.81 | 4.62 ± 0.85 | 0.005 |
LDL (mmol/L) | 16.28 ± 57.13 | 2.92 ± 0.73 | < 0.001 |
CA125 (IU/mL) | 16.70 ± 8.82 | 19.54 ± 16.95 | 0.655 |
ER range( %) | 0.73 ± 0.28 | 0.76 ± 0.21 | 0.970 |
PR range (%) | 0.82 ± 0.18 | 0.75 ± 0.28 | 0.923 |
p53 range (%) | 0.50 ± 0.48 | 0.30 ± 0.40 | 0.134 |
Ki-67 range (%) | 0.27 ± 0.19 | 0.20 ± 0.13 | 0.184 |
Menstruation regularity | 0.145 | ||
Yes | 3 (15.00%) | 53 (30.64%) | |
No | 17 (85.00%) | 120 (69.36%) | |
Gestation | 0.358 | ||
No | 17 (85.00%) | 107 (61.85%) | |
Yes | 3 (15.00%) | 66 (38.15%) | |
Parity | 0.034 | ||
No | 19 (95.00%) | 143 (82.66%) | |
Yes | 1 (5.00%) | 30 (17.34%) | |
PCOS | 0.307 | ||
No | 11 (55.00%) | 115 (66.47%) | |
Yes | 9 (45.00%) | 58 (33.53%) | |
Thyroid disease | 0.592 | ||
No | 17 (85.00%) | 154 (89.02%) | |
Yes | 3 (15.00%) | 19 (10.98%) | |
Family history | 0.835 | ||
No | 18 (90.00%) | 153 (88.44%) | |
Yes | 2 (10.00%) | 20 (11.56%) | |
Hypertension | 0.011 | ||
No | 15 (75.00%) | 160 (92.49%) | |
Yes | 5 (25.00%) | 13 (7.51%) | |
Diabetes | 0.870 | ||
No | 16 (80.00%) | 141 (81.50%) | |
Yes | 4 (20.00%) | 32 (18.50%) | |
Metformin use | 0.772 | ||
No | 11 (55.00%) | 101 (58.38%) | |
Yes | 9 (45.00%) | 72 (41.62%) | |
Medication use | 0.109 | ||
Single | 11 (55.00%) | 125 (72.25%) | |
Combined | 9 (45.00%) | 48 (27.75%) | |
Maintenance treatment | 0.030 | ||
No | 8 (40.00%) | 33 (19.08%) | |
Yes | 12 (60.00%) | 140 (80.92%) | |
Histological type | 0.010 | ||
AEH | 5 (25.00%) | 96 (55.49%) | |
Early EC | 15 (75.00%) | 77 (44.51%) | |
ER intensity | 0.014 | ||
+ | 6 (30.00%) | 86 (58.11%) | |
+ + | 2 (10.00%) | 21 (14.19%) | |
+ + + | 12 (60.00%) | 41 (27.70%) | |
PR intensity | 0.005 | ||
Negative | 0 (0.00%) | 5 (3.40%) | |
+ | 4 (20.00%) | 72 (48.98%) | |
+ + | 2 (10.00%) | 26 (17.69%) | |
+ + + | 14 (70.00%) | 44 (29.93%) | |
p53 | 0.408 | ||
Negative | 4 (21.05%) | 37 (30.33%) | |
Positive | 15 (78.95%) | 85 (69.67%) |
Screening of risk formula in FST patients
Variables | Univariate analysis HR (95% CI)/P-value | Multivariate analysis HR (95% CI)/P-value |
---|---|---|
Basic information | 2.18 (1.21, 6.05) 0.014 | 2.35 (1.05, 5.27) 0.037 |
Characteristics | 2.61 (1.33, 5.51) 0.006 | 3.78 (2.02, 279.71) 0.011 |
Blood pressure | 2.35 (1.33, 5.71) 0.004 | 18.54 (1.08, 319.43) 0.045 |
Glucose metabolism | 2.71 (1.54, 4.77) 0.001 | 12.54 (1.23, 127.98) 0.037 |
Lipid metabolism | 0.76 (0.47, 1.21) 0.254 | 8.32 (1.35, 51.34) 0.021 |
Immunohistochemistry | 2.68 (1.47, 4.90) 0.001 | 2.194 (1.10, 4.35) 0.025 |
Histological type | ||
AEH | 1.0 | 1.0 |
Early EC | 0.54 (0.38, 0.78) 0.001 | 0.63 (0.43, 0.93) 0.019 |
Medication method | ||
Combined medicine | 1.0 | 1.0 |
Single medicine | 0.40 (0.28, 0.57) < 0.001 | 0.46 (0.31, 0.68) 0.001 |
Maintenance treatment | ||
No | 1.0 | |
Yes | 1.08 (0.74, 1.58) 0.701 |